Ann D. Thor
#161,558
Most Influential Person Now
Ann D. Thor's AcademicInfluence.com Rankings
Ann D. Thorphilosophy Degrees
Philosophy
#9333
World Rank
#12873
Historical Rank
Logic
#6316
World Rank
#7825
Historical Rank

Download Badge
Philosophy
Ann D. Thor's Degrees
- Doctorate Medicine Harvard University
Why Is Ann D. Thor Influential?
(Suggest an Edit or Addition)Ann D. Thor's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Revision of the American Joint Committee on Cancer staging system for breast cancer. (2002) (1236)
- Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. (2000) (1104)
- c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. (1994) (979)
- Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. (1994) (908)
- Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. (1992) (810)
- erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. (1998) (625)
- Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas (1996) (621)
- Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008) (611)
- Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro (2009) (486)
- Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. (1986) (467)
- HER2 and response to paclitaxel in node-positive breast cancer. (2007) (433)
- Metformin induces unique biological and molecular responses in triple negative breast cancer cells (2009) (399)
- Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide (2014) (317)
- p53 gene mutations and protein accumulation in human ovarian cancer. (1993) (310)
- Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. (2001) (305)
- Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. (2003) (291)
- Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. (1994) (286)
- The art and science of cytopathology: Richard M. DeMay, MD. Chicago IL, ASCP Press, 1996, 2 vol set, 1,289 pages, $285 (1996) (266)
- Expression of ras oncogene p21 in prostate cancer. (1986) (265)
- Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53. (2006) (258)
- Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors (1993) (249)
- Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. (2010) (236)
- Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases (1984) (231)
- Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. (1984) (225)
- Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. (2005) (221)
- Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. (1988) (216)
- The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. (1992) (215)
- Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. (2004) (202)
- Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. (1985) (200)
- Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers (2012) (187)
- HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. (2000) (182)
- The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. (1998) (181)
- Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. (2000) (180)
- Ras oncogene mutations in benign and malignant thyroid neoplasms. (1991) (174)
- Downregulation of miR-342 is associated with tamoxifen resistant breast tumors (2010) (172)
- HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer (1997) (169)
- Invasive micropapillary carcinoma of the breast: a prognostic study. (1999) (167)
- Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. (1991) (165)
- Expression of laminin receptor in normal and carcinomatous human tissues as defined by a monoclonal antibody. (1985) (153)
- Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. (1986) (149)
- Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. (1999) (145)
- A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation (2001) (145)
- Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. (1986) (143)
- Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells (2007) (143)
- c-erbB-2 in breast cancer: development of a clinically useful marker. (2002) (137)
- Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions (2011) (136)
- p53 abnormalities in human parathyroid carcinoma. (1994) (133)
- Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. (1995) (132)
- Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3 (1987) (131)
- Monoclonal Antibody B72.3 Reactivity with Human Endometrium: A Study of Normal and Malignant Tissues (1987) (129)
- pS2 expression and response to hormonal therapy in patients with advanced breast cancer. (1991) (128)
- HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. (2000) (124)
- Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. (2001) (123)
- Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. (2005) (122)
- Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. (1989) (120)
- Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. (1995) (119)
- Age-associated biomarker profiles of human breast cancer. (2002) (116)
- Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. (2005) (114)
- The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). (1986) (113)
- ras gene alterations and enhanced levels of ras p21 expression in a spectrum of benign and malignant human mammary tissues. (1986) (112)
- Ovarian small cell carcinoma. Histogenetic considerations based on immunohistochemical and other findings. (1989) (110)
- Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. (1985) (109)
- Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue. (1990) (108)
- Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. (2004) (108)
- Glucose promotes breast cancer aggression and reduces metformin efficacy (2013) (106)
- erbB-2 (HER-2) and Breast Cancer Progression (2003) (100)
- Systemic Gene Delivery Expands the Repertoire of Effective Antiangiogenic Agents* (1999) (96)
- Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. (2001) (87)
- Ets regulation of the erbB2 promoter (2000) (87)
- Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b (2014) (85)
- p53 mutations in benign breast tissue. (1995) (84)
- Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. (1988) (82)
- Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. (2002) (81)
- Ovarian, peritoneal, and endometrial serous carcinoma: clonal origin of multifocal disease. (1996) (79)
- p53 gene analysis of ovarian borderline tumors and stage I carcinomas. (1995) (78)
- Ovarian Endometrioid Carcinomas Resembling Sex Cord–Stromal Tumors. An Immunohistochemical Study (1989) (75)
- Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. (1986) (73)
- p53 expression in ovarian borderline tumors and stage I carcinomas. (1994) (73)
- Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. (2003) (72)
- Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization. (1987) (70)
- Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models (2013) (68)
- Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling (2014) (68)
- Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. (1984) (68)
- Pharmacokinetics of radiolabeled monoclonal antibody B6.2 in patients with metastatic breast cancer. (1986) (66)
- Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study (2004) (65)
- Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer (2016) (63)
- The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. (2008) (62)
- Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. (2012) (60)
- Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. (1997) (60)
- Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas. (1987) (56)
- Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. (2009) (54)
- Tumor‐associated glycoprotein (TAG‐72) detected in adenocarcinomas and benign lesions of the stomach (1986) (54)
- Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. (2005) (54)
- Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice (2002) (52)
- The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. (1994) (51)
- Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells (2010) (51)
- Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. (1993) (50)
- Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression (2010) (50)
- Histologic demonstration of antigens reactive with anti-p21 ras monoclonal antibody (RAP-5) in human stomach cancers. (1986) (48)
- Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-α induced apoptosis (2006) (48)
- Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. (2009) (47)
- Prognostic and Predictive Value of Tumor Vascular Endothelial Growth Factor Gene Amplification in Metastatic Breast Cancer Treated with Paclitaxel with and without Bevacizumab; Results from ECOG 2100 Trial (2013) (47)
- Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues. (1987) (45)
- Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer (2013) (45)
- Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3. (1986) (45)
- Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells (2005) (44)
- Functional identification of distinct sets of antitumor activities mediated by the FKBP gene family (2003) (43)
- p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome (2000) (42)
- Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. (2010) (41)
- Bcl-2 overexpression sensitizes MCF-7 cells to genistein by multiple mechanisms. (2007) (41)
- Altered expression of the DNA repair protein, N‐methylpurine‐DNA glycosylase (MPG), in breast cancer (1998) (40)
- HER2--a discussion of testing approaches in the USA. (2001) (40)
- Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198) (2015) (39)
- Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. (2005) (39)
- Monoclonal antibodies and breast cancer. (1986) (38)
- Histopathologic Characteristics Predicting HER-2/neu Amplification in Breast Cancer (2007) (37)
- HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. (2006) (37)
- Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3. (1986) (35)
- p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription (2012) (34)
- Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer (2018) (34)
- Tumor‐associated glycoprotein (TAG‐72) expression in ulcerative colitis (1989) (34)
- Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo (2017) (32)
- Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. (1991) (32)
- Surface expression of tumor-associated antigens in primary cultured human colonic epithelial cells from carcinomas, benign tumors, and normal tissues. (1985) (32)
- p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905) (2011) (32)
- Pathology of the fallopian tube, broad ligament, peritoneum, and pelvic soft tissues. (1991) (32)
- Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. (1989) (32)
- Caspase 3 activation during herpes simplex virus 1 infection. (2006) (29)
- Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling (2009) (27)
- Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C), and trastuzumab (T) in HER-2/neu (+)advanced non-small cell lung cancer (nsclc): early analysis of e2598 (2001) (27)
- Immunohistochemical evaluation of ras oncogene expression in pulmonary and pleural neoplasms (1987) (26)
- Are patterns of HER-2/neu amplification and expression among primary tumors and regional metastases indicative of those in distant metastases and predictive of Herceptin response? (2001) (26)
- ErbB-2 protein in sera and tumors of breast cancer patients (1998) (26)
- FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. (2018) (26)
- Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases (2017) (26)
- p53 analysis in diagnostic pathology. Biologic implications and possible clinical applications. (1993) (25)
- The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells (2015) (23)
- Applications of immunocytochemistry to clinical cytology. (1987) (23)
- Caspase expression profile and functional activity in a panel of breast cancer cell lines. (2007) (22)
- COMMENT ON: TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST CARCINOMA. AUTHORS' REPLY (1995) (21)
- Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. (1994) (21)
- Benign metastasizing pleomorphic adenoma of salivary gland: Diagnosis of bone lesions by fine‐needle aspiration biopsy (1992) (21)
- p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma. (1994) (20)
- Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity. (1987) (19)
- Modulation of human tumor antigen expression. (1987) (18)
- Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients (2005) (18)
- Detection of adenocarcinoma in peritoneal washings by staining with monoclonal antibody B72.3. (1989) (18)
- POST‐HYSTERECTOMY CARCINOMA OF THE FALLOPIAN TUBE MIMICKING A VESICOVAGINAL FISTULA (1992) (17)
- ras oncogene p21 expression in hepatocellular carcinoma. (1989) (17)
- Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions (2005) (16)
- Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow (1988) (16)
- Immunological characterization of a novel human colon‐associated antigen (CAA) by a monoclonal antibody (1987) (15)
- Reactivity of the monoclonal antibody B72.3 with fetal antigen: correlation with expression of TAG-72 in human carcinomas. (1988) (15)
- A Revised Staging System for Breast Cancer (2004) (15)
- Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells (2018) (14)
- Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. (2003) (14)
- Paratesticular adenomatoid tumors. The cytologic presentation in fine needle aspiration biopsies. (1989) (13)
- The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer (2017) (13)
- Immunohistochemical analysis of normal and mutated ras oncogene p21 expression in human pulmonary and pleural neoplasms (1988) (13)
- Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. (2015) (12)
- Spermatic granuloma. Diagnosis by fine needle aspiration cytology. (1989) (12)
- Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem (2020) (12)
- Phenotypic heterogeneity of a tumor-associated antigen in adenocarcinomas of the colon and their metastases as demonstrated by monoclonal antibody B72.3. (1986) (12)
- Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. (2004) (11)
- Tumor targeting with monoclonal antibody B72.3: experimental and clinical results. (1990) (11)
- Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. (2008) (10)
- Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers (2016) (9)
- Prognostic factors in breast cancer: Integrating the cytology laboratory (1992) (9)
- Expression of ras oncogene p21 during human fetal development as determined by monoclonal antibodies RAP-5, Y13-259, and DWP (1988) (9)
- Enhancement of tumor‐associated glycoprotein‐72 antigen expression in hormone‐related ovarian serous borderline tumors (1991) (8)
- pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival (2005) (7)
- Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 & ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148). (2009) (7)
- Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer (E2198) (2001) (6)
- HER2 testing: laboratory, technical and clinical considerations. (2000) (6)
- Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells. (2017) (6)
- Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC (2021) (6)
- Metformin Activity against Breast Cancer: Mechanistic Differences by Molecular Subtype and Metabolic Conditions (2020) (6)
- Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers (2020) (6)
- Radiolocalization of colon cancer with I-131 B72. 3 monoclonal antibody (1985) (6)
- Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells (2017) (6)
- TAG-72 as a Tumor Marker (1992) (5)
- Pathology and genetic testing (1997) (5)
- Pathology in gynecology and obstetrics (ed 4) (1994) (5)
- ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients (2020) (5)
- 16 – Colon Carcinoma Cell Population as Defined by Monoclonal Antibodies (1990) (4)
- Understanding the age dependency of breast cancer biomarkers. (2003) (4)
- Abstract 2967: Metformin selectively targets tumor initiating cells in erbb-2 overexpressing breast cancer models (2014) (4)
- AIDS-related Cryptococcus neoformans choroiditis (2020) (3)
- Phase II Eastern Cooperative Oncology Group (ECOG) pilot study of paclitaxel (P), carboplatin (C) and Herceptin (H) in HER2/neu (+) advanced NSCLC: Preliminary analysis (2000) (3)
- Biodistribution of monoclonal antibody B72. 3(I-131) in colon cancer patients (1985) (3)
- Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. (1991) (3)
- Vascular endothelial platelet endothelial cell adhesion molecule 1 (PECAM-1) regulates advanced metastatic progression (Proceedings of the National Academy Sciences of the United States of America (2010) 107, 43 (18616-18621)) (2011) (3)
- C-erb B-2 Expression in women with node-positive early breast cancer (1995) (3)
- P-628 Trastuzumab in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer: Final report of ECOG 2598 (2003) (2)
- Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells. (2009) (2)
- Epidermal growth factor receptor expression in breast cancer (2005) (2)
- PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN HUMAN NERVOUS SYSTEM TUMORS: 34 (1990) (2)
- Monoclonal antibody RAP-5 and ras p21 expression. (1988) (2)
- Abstract 72: Metformin enhances tumor regression and reduces tumor burden in a preclinical paradigm modeling obesity's impact on postmenopausal breast cancer (2010) (1)
- Histochemistry in pathology 2E review (ed 2): M. I. Filipe and B. D. Lake (eds). New York, NY, Churchill Livingstone, 1990, 496 pages (1992) (1)
- Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer (2021) (1)
- Abstract P1-08-02: Metformin blocks de novo synthesis of cholesterol in triple negative breast cancer cells (2015) (1)
- Abstract 4756: Elucidating the role of AR in breast cancer . (2013) (1)
- Uniformly positive (>80%) HER2 expression maximizes sensitivity and specificity for prediction of response to trastuzumab in CALGB 9840. (2009) (1)
- Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling (2014) (1)
- Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 ) (2011) (1)
- Retrospective analysis of c- erb B-2 and PS2 in early breast cancer before and after local failure (1990) (1)
- Thymidilate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD), and dihydrofolate reductase (DHFR) as predictive markers of capecitabine efficacy in breast cancer patients. (2009) (1)
- Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification: Evaluation According to ASCO/CAP Criteria: Brunelli M, Manfrin E, Martignoni G, et al (Univ of Verona, Italy; et al) Am J Clin Pathol 131:678-682, 2009§ (2009) (1)
- The application of monoclonal antibodies in the cytologic evaluation of tumors. (1990) (1)
- Abstract P5-10-04: Metformin mediated upregulation of microRNA-193 triggers apoptosis by decreasing fatty acid synthase (2012) (1)
- A comparison between DASL and Affymetrix on probing the whole-transcriptome (2016) (1)
- Estrogenic Promotion of ErbB 2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB 3 Signaling (2009) (1)
- Abstract B20: Role of ErbB3 in tumorigenesis and drug resistance in ErbB2-driven breast cancer (2015) (1)
- 4–4 p95HER-2 Predicts Worse Outcome in Patients With HER-2-Positive Breast Cancer (2007) (0)
- Thymidilate synthase gene copy number as predictive marker of capecitabine efficacy in patients with breast cancer. (2011) (0)
- Abstract 4604: PTP4A3 is oncogenic and modulates triple negative breast cancer growth (2014) (0)
- Enhanced Expression of e-1la-ras p21 in Human Stomach Adenocarcinomas Defined by Immunoassays Using Monoclonal Antibodies and in Situ Hybridization (2006) (0)
- Cytopathology of soft tissue and bone tumors (1990) (0)
- Abstract P1-05-01: Characterization of human postpartum breast involution: Implications for young women’s breast cancer (2013) (0)
- Response: Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer (1999) (0)
- Abstract P5-05-02: Thyroid hormone replacement therapy shortens survival in hormone receptor positive early stage breast cancers (2019) (0)
- Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers (2021) (0)
- COMMENT ON: ERBB-2, P53, AND EFFICACY OF ADJUVANT THERAPY IN LYMPH NODE-POSITIVE BREAST CANCER. AUTHORS' REPLY (1999) (0)
- PECAM‐1 and Tumor Metastasis (2007) (0)
- Immunology: Basic concepts, diseases, and laboratory methods: J. Helen Cronenberger, J Charles Jenette. Norwalk, CT, Appleton and Lange, 287 pages, $26.95 (1989) (0)
- Breast Cancer Risk Associated With Estrogen Receptor Expression in Epithelial Hyperplasia Lacking Atypia and Adjacent Lobular Units (2005) (0)
- Helene Smith: A Memorial (2004) (0)
- Abstract IA18: Targeting the androgen receptor in multiple breast cancer subtypes (2013) (0)
- Tumor and Stem Cell Biology Obesity and Overfeeding Affecting Both Tumor and Systemic Metabolism Activates the Progesterone Receptor to Contribute to Postmenopausal Breast Cancer (2012) (0)
- Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide (2014) (0)
- Genistein converts Bcl-2 into a proapoptotic protein in Bcl-2 overexpressing MCF-7 breast cancer cells. (2006) (0)
- Abstract P3-04-11: Thyroid hormone up-regulates estrogenic and pro-carcinogenic signaling, inducing a basaloid and more motile phenotype in only steroid receptor positive breast cancer cells (2015) (0)
- 2-Chlorodeoxyadenosine (2-CDA) and Dexamethasone Induce Apoptosis in Multiple Myeloma (MM) Via Different Mechanisms. (2007) (0)
- 4–24 Phyllodes Tumors of the Breast: The Role of Pathologic Parameters (2006) (0)
- Selective Effects of Glucose, Insulin and Leptin by Molecular Breast Cancer Subtype. (2009) (0)
- Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer (2018) (0)
- Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer (2013) (0)
- Diagnosis of endometrial biopsies and curettings: A practical approach: Michael T. Mazur and Robert J. Kurman. New York, Springer-Verlag, 260 pages, 1995, $79.00 (1996) (0)
- Tumor progression and metastasis. UCLA symposia on Molecular and Cellular Biology, vol 78 (1989) (0)
- Tumor Associated Antigens and Oncogene Products Defined by Monoclonal Antibodies (1987) (0)
- Transabdominal fine-needle aspiration biopsy:Liange-Che Tao, New York, NY, Igaku-Shoin, 1990, 496 pages, $88.75 (1990) (0)
- Metabolomics of basal breast carcinomas: a potential target for treatment intervention. (2009) (0)
- Prognostic and Predictive Markers in Breast Cancer: Issues Related to Molecular Determinants of Outcome (1998) (0)
- Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer (2022) (0)
- Potential Clinical Application of a Monoclonal Antibody to a Tumor Associated Glycoprotein (TAG-72) (1985) (0)
- 3–31 uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues (2007) (0)
- Editorial comments: Detection of abnormal p53 protein levels in cytology specimens: Present and future applications (1995) (0)
- P5-01-06: Gene Copy Number and Expression of TYMP and TYMS Are Predictive of Outcome in Breast Cancer Patients Treated with Capecitabine. (2011) (0)
- Abstract P5-10-05: Novel Mechanisms of Metformin Action in TN Breast Cancer: Upregulation of miRNA 141 and 192, are Associated with a Decrease in TargetsGRB2andMSNInvolved in Signaling and Motility Respectively (2012) (0)
- Abstract PS19-18: Metformin exhibits cytotoxicity effects on triple-negative cancer cells via TRAIL-mediated apoptosis (2021) (0)
- Practical cytopathology: RW Astarita (ed). New York, NY, Churchill Livingstone, 1989, 472 pages, $110 (1990) (0)
- Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients. (2012) (0)
- Abstract 1971: ESE-1 controls transformation properties in HER2+ breast cancer cells, and predicts poor prognostic status and survival in breast cancer patients (2015) (0)
- Metformin-induced TRAIL Upregulation Promotes Apoptosis in Triple Negative Breast Cancer and Non-small Cell Lung Cancer Cells (2020) (0)
- Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells (2018) (0)
- Monoclonal Antibodies Generated to a Synthetic Peptide Define Ras Gene Expression at the Single Cell Level in Human Colon and Mammary Carcinomas (1985) (0)
- Abstract CN13-04: Obesity, insulin resistance, hyperglycemia, and cancer: A novel role for metformin as an anticancer drug (2010) (0)
- Clinical cytopathology and aspiration biopsy (1990) (0)
- Infectious and inflammatory diseases and other non-neoplastic disorders (1992) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Ann D. Thor?
Ann D. Thor is affiliated with the following schools: